PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights
PMV Pharmaceuticals (NASDAQ:PMVP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics [Yahoo! Finance]